PRIMARY, NONVIRAL, HEPATOCELLULAR CARCINOMA IN PATIENTS WITH PROSTATE CANCER TREATED BY HORMONE THERAPY

DOI Web Site PubMed 2 Citations 18 References
  • Hasegawa Yuichi
    Department of Urology, Jikei University School of Medicine
  • Tomita Masayuki
    Department of Urology, Jikei University School of Medicine
  • Asano Koji
    Department of Urology, Jikei University School of Medicine
  • Hasegawa Norio
    Department of Urology, Jikei University School of Medicine
  • Ikemoto Isao
    Department of Urology, Jikei University School of Medicine
  • Onodera Shoichi
    Department of Urology, Jikei University School of Medicine
  • Ohishi Yukihiko
    Department of Urology, Jikei University School of Medicine
  • Ishikawa Tomohisa
    Division of Gastroenterology and Hepatology Department of Internal medicine, Jikei University School of Medicine

Bibliographic Information

Other Title
  • 前立腺癌の内分泌療法中に発生した非ウイルス性肝細胞癌の2例
  • 症例報告 前立腺癌の内分泌療法中に発生した非ウイルス性肝細胞癌の2例
  • ショウレイ ホウコク ゼンリツセンガン ノ ナイブンピ リョウホウ チュウ ニ ハッセイ シタ ヒウイルスセイ カン サイボウガン ノ 2レイ
  • 2 CASE REPORTS

Search this article

Description

We studied two cases of primary, hepatocellular carcinoma (HCC) that occurred following hormone therapy (estrogen therapy in one case and total androgen blockade therapy in another) for stage D2 prostate cancer. Prostate cancer is considered to be hormone-dependent, and androgens appear to be important hormonal factors. However, hepatocellular carcinoma has been shown to have both estrogen and androgen receptors, suggesting that this may be dependent on estrogen or androgen. Reported here are two unique cases of hepatocellular carcinoma in patients with prostate cancer; the pathogenesis of HCC in these patients was suspected to be related to diethylstilbestrol (DES) therapy and antiandrogen therapy for their prostate cancer.

Journal

Citations (2)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top